Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in metastatic colorectal cancer
NL-OMON39372Phase 2Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Feb 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tivozanib, bevacizumab, oxaliplatin, folinic acid and fluorouracil in colorectal cancer (CRC) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Progression-free survival. Started Feb 2013; status: active, not recruiting.
02
Drugs
tivozanibbevacizumaboxaliplatinfolinic acidfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON39372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39372.